

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1548)**

**APPOINTMENT OF INDEPENDENT  
NON-EXECUTIVE DIRECTORS AND CHANGE IN  
COMPOSITION OF BOARD COMMITTEE**

The Board is pleased to announce that Mr. Cheung Yiu Leung Andy (張耀樑) and Dr. Shi Chenyang (施晨陽) have been appointed as independent non-executive Directors and members of the Nomination Committee with effect from 12 April 2024.

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

The Board is pleased to announce that Mr. Cheung Yiu Leung Andy (張耀樑) (“**Mr. Cheung**”) and Dr. Shi Chenyang (施晨陽) (“**Dr. Shi**”) have been appointed as independent non-executive Directors and members of the nomination committee of the Company (the “**Nomination Committee**”) with effect from 12 April 2024.

The biographical details and other information of Mr. Cheung and Dr. Shi are set out below:

**Mr. Cheung**, aged 64, has over 30 years of professional accounting and auditing experience. He has been a member of Hong Kong Institute of Certified Public Accountants since October 1986 and was a member of its disciplinary panel from January 2015 to December 2020.

Mr. Cheung is currently serving as a director in various public companies in Hong Kong and the United States. Mr. Cheung has been an independent non-executive director and chairman of the audit committee of each of JW (Cayman) Therapeutics Co. Ltd and Hua Medicine, companies the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) (stock codes 2126 and 2552 respectively) since October 2020 and January 2023 respectively. In addition, Mr. Cheung has been an independent non-executive director and chairman of the audit committee of CanSino Biologics Inc., a company the shares of which are listed on the Hong Kong Stock Exchange (stock code: 6185) and Shanghai Stock Exchange (stock code: 688185), since February 2024. He is also an independent director and the chairman of audit committee of Adagene Inc., a company the shares of which are listed on Nasdaq Stock Market (stock code: ADAG), since February 2021.

From July 2018 to June 2020, Mr. Cheung was the deputy area managing partner of Ernst & Young (“EY”) in Asia Pacific, overseeing its business operations, finance, information technology and risk management functions. During the same period, Mr. Cheung was a member of each of the EY Asia Pacific’s Area Operating Executives, EY’s Global Accounts Committee and EY’s Global Markets and Investment Committee. From July 2013 to June 2018, Mr. Cheung was EY’s assurance managing partner in Greater China, managing its audit, financial accounting advisory, forensic and climate changes and sustainability services. During that period, he was also a member of EY Greater China’s leadership team. Mr. Cheung’s other prior responsibilities with EY include his service as the chief operating officer of EY Hua Ming LLP from July 2011 to June 2013, an assurance partner of EY China from July 2010 to June 2011 and the area chief financial officer of EY Asia Pacific from July 2009 to June 2010. Prior to joining EY in September 2006, Mr. Cheung was an assurance partner with PricewaterhouseCoopers Zhong Tian LLP and an assurance partner with Arthur Andersen in China and Hong Kong successively.

Mr. Cheung obtained a bachelor’s degree in accounting and finance from the University of Lancaster in the United Kingdom in June 1982, and a master’s degree in accounting and finance from London School of Economics in the United Kingdom in August 1983.

Although Mr. Cheung was the former deputy area managing partner at EY, which is the auditor of the Company as at the date of this announcement, before his retirement in June 2020, the Nomination Committee and the Board are of the view that Mr. Cheung has satisfied the independence requirements for independent non-executive Directors under Rule 3.13 of the Listing Rules taking into account the following factors: (i) Mr. Cheung has ceased to be a partner of EY for more than two years immediately prior to his proposed appointment as an independent non-executive Director, (ii) throughout his service in EY, Mr. Cheung (a) did not serve as a member or leader of the execution team in providing audit or consulting services to the Company, (b) did not serve as an audit partner or engagement partner of EY in providing services to the Company, and (c) had never been consulted on or involved in providing technical supports related to EY’s audit services to the Company, (iii) since his retirement from EY, Mr. Cheung has not been involved nor has he participated in any transaction between the Company and EY, and (iv) Mr. Cheung has met all of the requirements under Rule 3.13 of the Listing Rules. The Company has demonstrated to the satisfaction of the Hong Kong Stock Exchange that Mr. Cheung is independent and fulfills all independence requirements under Rule 3.13 of the Listing Rules.

**Dr. Shi**, aged 56, has over 30 years of experience in life science research and development, sales and marketing, business development and investment. Since January 2017, Dr. Shi has been the managing partner of Serica Partners, a China-based venture fund focused on the investment in in vitro diagnostics (“IVD”) and medical devices in China. Dr. Shi has been the chairperson of careLYFE Co., Ltd., a company dedicated to innovating medical technologies such as new cancer oncology biomarkers, precision diagnosis, and internet medical services, since December 2017. Dr. Shi has been a board member of Guangzhou AnchorDx Medical Co., Ltd., a diagnostics company focused on developing cancer early detection tests, since October 2017.

Dr. Shi previously served as executive director and chief executive officer of Adicon International Limited, a leading independent clinical laboratory in China, from October 2018 to April 2019, and from April 2019 to May 2020, respectively. From February 2017 to March 2019, Dr. Shi served as director and chief executive officer of NuProbe Global, Inc., a liquid biopsy technology company which he co-founded. He was the President Asia Pacific of QIAGEN N.V., a leading company focused on IVDs and life science research tools whose shares are listed on NASDAQ (stock code: QGEN) and the Frankfurt Stock Exchange (stock code: QIA) respectively, from October 2005 to February 2015. Prior to joining QIAGEN N.V., Dr. Shi held senior positions at Bridge Pharmaceuticals, GenoSpectra Inc. (renamed as Panomics Inc. since February 2006) and A.M. Pappas&Associates, and served as a faculty member at the School of Medicine of National University of Singapore.

Dr. Shi was a founding director of BayHelix Group, a global association of Chinese life science business

executives, and was elected Chairman from January 2017 to January 2019. Dr. Shi has been a member on the Biotech Advisory Panel of Hong Kong Stock Exchange since April 2018.

Dr. Shi obtained his doctoral degree in biophysics and master's degree in science from the University of Rochester in New York, the United States in April 1991 and January 1989 respectively, and a bachelor's degree in science from University of Science and Technology of China in China in July 1986.

Pursuant to the letters of appointment made between the Company and each of Mr. Cheung and Dr. Shi (collectively, the “**Letters of Appointment**”), the appointments of Mr. Cheung and Dr. Shi will be for an initial term of three years commencing from 12 April 2024. They are subject to retirement by rotation and eligible for re-election pursuant to the memorandum of association and the articles of association of the Company and the Listing Rules. Therefore, Mr. Cheung and Dr. Shi will hold office until the next annual general meeting of the Company at which they will be eligible for re-election. According to the Letters of Appointment, each of Mr. Cheung and Dr. Shi is entitled to an annual remuneration of HK\$480,000, which has been recommended by the remuneration committee of the Company and approved by the Board with reference to their duties and responsibilities in the Company and the prevailing market condition.

Both Mr. Cheung and Dr. Shi have obtained legal advice pursuant to Rule 3.09D of the Listing Rules and have confirmed that they understood their obligations as a director of the Company. The Company has received written confirmations of independence according to Rule 3.13 of the Listing Rules from Mr. Cheung and Dr. Shi.

As at the date of this announcement, Mr. Cheung and Dr. Shi respectively confirmed that (i) they do not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) neither of them holds any position with the Group; (iii) save as disclosed above, Mr. Cheung and Dr. Shi do not and have not held any directorship in any public listed companies in Hong Kong or overseas in the past three years nor any other major appointments and qualifications; (iv) they do not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company or its subsidiaries or any of their respective associates (as defined in the Listing Rules) of the Company; (v) there is no other information in relation to Mr. Cheung and Dr. Shi that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and (vi) there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with Mr. Cheung and Dr. Shi's appointments as independent non-executive Directors and each a member of the Nomination Committee.

The Board would like to express its warmest welcome to Mr. Cheung and Dr. Shi for joining the Board.

## CHANGE IN COMPOSITION OF BOARD COMMITTEE

Following the above-mentioned changes to the Nomination Committee, the Nomination Committee would comprise one executive director of the Company, namely Mr. Meng Jiange (as the Chairman), and four independent non-executive Directors, namely Mr. Pan Juan, Mr. Dai Zumian, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang as members.

By order of the Board  
**Genscript Biotech Corporation**  
**MENG Jiange**  
*Chairman and Executive Director*

Hong Kong, 12 April 2024

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Juan, Dr. Wang Xuehai, Mr. Cheung Yiu Leung Andy and Dr. Shi Chenyang.*

\* *For identification purposes only*